Literature DB >> 11718746

Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study.

K Shiozaki1, E Iseki, H Hino, K Kosaka.   

Abstract

Of the five subtypes (m1-m5) of muscarinic acetylcholine receptors (mAChR), the m1 subtype is the most abundant in the human cerebral cortex and hippocampus. Impairment of the muscarinic cholinergic system in the brain may cause cognitive dysfunction in patients with Alzheimer's disease (AD), and choline esterase inhibitors (ChE-I) are used to improve cognitive dysfunction. Severe impairment of the cholinergic system has also been reported in the brains of subjects with dementia with Lewy bodies (DLB). There have been a few reports about the distribution of mAChR subtypes in the human brain. In the present study, we investigated the distribution of m1 mAChR in the human hippocampus using an antibody against the m1 subtype. In the control brains, m1 immunoreactivity was observed in the apical dendrites and cell bodies of granular neurons of the dentate gyrus and pyramidal neurons of CA1-3 and the subiculum. The dendrites and the cell bodies of the pyramidal neurons in layers III and V of the parahippocampal cortex and other temporal cortices were also positive for m1 immunoreactivity. This m1 immunoreactivity was markedly reduced in AD and DLB brains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718746     DOI: 10.1016/s0022-510x(01)00638-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

Review 1.  The hippocampus and cognitive impairments.

Authors:  E B Arushanyan; E V Beier
Journal:  Neurosci Behav Physiol       Date:  2008-10

2.  Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

Authors:  Rodrigo Medeiros; Masashi Kitazawa; Antonella Caccamo; David Baglietto-Vargas; Tatiana Estrada-Hernandez; David H Cribbs; Avraham Fisher; Frank M LaFerla
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

Review 3.  Cholinergic modulation of the hippocampal region and memory function.

Authors:  Juhee Haam; Jerrel L Yakel
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

4.  Excitatory and inhibitory effects of HCN channel modulation on excitability of layer V pyramidal cells.

Authors:  Tuomo Mäki-Marttunen; Verónica Mäki-Marttunen
Journal:  PLoS Comput Biol       Date:  2022-09-13       Impact factor: 4.779

Review 5.  Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems.

Authors:  Boyi Zong; Fengzhi Yu; Xiaoyou Zhang; Wenrui Zhao; Peng Sun; Shichang Li; Lin Li
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

Review 6.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

7.  Muscarinic modulation of erg potassium current.

Authors:  Wiebke Hirdes; Lisa F Horowitz; Bertil Hille
Journal:  J Physiol       Date:  2004-07-02       Impact factor: 5.182

8.  M1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons.

Authors:  Allan T Gulledge; David J Bucci; Sunny S Zhang; Minoru Matsui; Hermes H Yeh
Journal:  J Neurosci       Date:  2009-08-05       Impact factor: 6.167

Review 9.  Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.

Authors:  Samantha E Yohn; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2017-09-09       Impact factor: 5.250

10.  Intrahippocampal blockade of nicotinic or muscarinic receptors fails to impair nonnavigational spatial memory in macaques.

Authors:  Elyssa M LaFlamme; Ludise Malkova; Patrick A Forcelli
Journal:  Behav Neurosci       Date:  2021-02-25       Impact factor: 2.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.